EXTEND, Phase 2 Trial Evaluating the Safety and Efficacy of Exercise Training in Men with Hormone Naïve Prostate Cancer - Mike Harrison

(Length of interview: 16 min)

Mike Harrison and Chuck Ryan dialogue on the specifics of the EXTEND trial. This is a phase 2 trial evaluating the safety and efficacy of exercise training in men receiving enzalutamide plus conventional ADT for hormone naïve prostate cancer. The discussion ensues to the value of exercise in this patient population and some of the nuances in managing patients in this type of trial.

Michael Roger Harrison, MD, Associate Professor of Medicine, Member of the Duke Cancer Institute

Charles J. Ryan, MD


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.